Lung cancer treatment has changed dramatically over the past two decades. Alongside surgery, radiation, chemotherapy, and immunotherapy, there is now a category of medicines known as targeted therapy. These treatments work differently from traditional chemotherapy, and for some people with lung cancer, they can offer meaningful control of the disease with a side effect profile that is often — though not always — easier to manage.
This guide is written for patients, caregivers, and anyone trying to understand what targeted therapy is and where it fits into lung cancer care. You will learn how these drugs work, why genetic testing of the tumor comes first, which molecular targets are commonly treated, what side effects may occur, and what questions are worth asking a care team.
What Is Targeted Therapy?
Targeted therapy refers to medicines designed to interfere with specific molecules that help cancer cells grow, divide, and survive. Instead of broadly attacking all rapidly dividing cells — which is how chemotherapy works — targeted drugs aim at particular proteins or genetic changes that are driving the cancer.
Many of these changes are called driver mutations. A driver mutation is an alteration in a gene that gives cancer cells a growth advantage. When a lung tumor depends heavily on one such altered protein, blocking that protein can slow or shrink the cancer.
Two important points are worth keeping in mind:
- Targeted therapy is not the same as immunotherapy. Immunotherapy helps the immune system recognize and attack cancer. Targeted therapy blocks specific molecular signals inside cancer cells.
- Not every lung cancer has a treatable target. Roughly speaking, targetable changes are more common in certain types of non-small cell lung cancer, but they can appear in others as well. Testing is the only way to know.
Why Biomarker Testing Comes First
Before targeted therapy can be considered, a sample of the tumor usually needs to be tested. This is often called biomarker testing, molecular testing, or genomic profiling. The goal is to look for specific gene changes that a drug could act on.
How the testing is done
Testing is typically performed on tissue collected during a biopsy. When tissue is limited or a biopsy is not practical, a blood sample may be used — sometimes called a liquid biopsy — to look for fragments of tumor DNA circulating in the blood.
Results are usually reported as a list of genes with or without detectable alterations. A care team then interprets those findings alongside the cancer’s stage, type, and the person’s overall health.
Common targets in lung cancer
A number of molecular targets have approved treatments. These include, among others:
- EGFR — one of the most commonly treated targets in lung adenocarcinoma
- ALK and ROS1 — rearrangements that can occur in younger patients and in people who have never smoked
- BRAF — including the V600E alteration
- KRAS — including the G12C alteration
- MET — including exon 14 skipping alterations
- RET — gene fusions
- HER2 — certain mutations
- NTRK — rare fusions found across many cancer types
This list continues to grow as research advances, and testing panels are often updated to include newly recognized targets.
How Targeted Therapy Is Given
Most targeted therapies for lung cancer are taken as oral tablets or capsules at home, usually once or twice daily. Some are given intravenously at a clinic. Because many are pills, treatment can often fit more easily into daily life than chemotherapy infusions.
Treatment is generally continued for as long as it is helping and remains tolerable, with regular imaging scans and check-ins to monitor response.
Potential Side Effects
Because targeted therapies are more selective than chemotherapy, they tend to spare hair and blood counts more often. However, they are not side-effect free. Common issues vary by drug and may include:
- Skin rash, dryness, or sensitivity to sun
- Diarrhea or other digestive changes
- Fatigue
- Nausea or decreased appetite
- Liver enzyme changes detected on blood tests
- Swelling, mouth sores, or nail changes
- Rarely, lung inflammation, heart rhythm changes, or other organ-specific effects
Many side effects can be prevented or reduced with proactive management — moisturizers, sun protection, dietary adjustments, dose modifications, or supportive medications. Reporting symptoms early is far more effective than waiting until they become severe.
Benefits and Limitations
Targeted therapy can produce significant tumor shrinkage and extend the time before the cancer progresses, sometimes with a quality of life that compares favorably to other options. For some targets, response rates are high.
There are limits, too:
- The cancer must have the target. Without a matching alteration, these drugs are unlikely to help.
- Resistance develops over time. Cancer cells can adapt and find new ways to grow, which is why regular monitoring matters.
- Effectiveness varies by target and by person. Two people with the same mutation may respond differently.
What happens when resistance occurs
When a targeted therapy stops working, options may include a different targeted drug that addresses the new resistance pattern, chemotherapy, immunotherapy, radiation to specific spots, or enrollment in a clinical trial. Repeat testing — sometimes on a new biopsy or blood sample — can help clarify the best next step.
Who May Be a Candidate
Targeted therapy is most often considered for people with advanced or metastatic non-small cell lung cancer that carries a matching molecular alteration. It is also used in some earlier-stage settings as part of a broader treatment plan. In small cell lung cancer, targetable alterations are far less common, though research continues.
Other factors matter as well, including kidney and liver function, other medical conditions, and medications already being taken, since some drugs interact with targeted therapies.
Questions Worth Asking Your Care Team
- Has my tumor been tested for molecular changes, and which ones were found?
- If no target was found, is repeat or broader testing an option?
- Which targeted therapy is being recommended, and why?
- What side effects should I watch for, and when should I call?
- How often will scans or blood tests be done to check whether it is working?
- What are the alternatives, including clinical trials?
The Bottom Line
Targeted therapy is a personalized approach to lung cancer treatment. It relies on identifying specific genetic changes in a tumor and using medicines that block those changes directly. For people whose cancers carry a matching alteration, it can offer meaningful disease control, often with manageable side effects and the convenience of at-home oral dosing.
The key steps are straightforward: get the tumor tested, review the results with a qualified care team, and monitor closely over time. Because this field evolves quickly, guidelines and available options can change from year to year.
If you or someone you care about is facing a lung cancer diagnosis, discussing biomarker testing early can open the door to the most appropriate treatment plan. For more plain-language guidance on symptoms, conditions, treatments, and everyday health, explore the related topics available in our health library.